Dr Gerhard Dahlhoff - Rhenium-SCT®: New method for the treatment of basal and squamous cell carcinoma
22 Jan 2021
Dr Gerhard Dahlhoff's talk from the BIR's event 'State-of-the-art nuclear medicine and pipeline industry developments'.
This one-day virtual event provided a platform for industry to demonstrate their current products and discuss their pipeline products that will soon be available. This allowed participants to become aware of what the state-of-the-art products in nuclear medicine are and helped them decide what may best suit their needs to improve services.
Educational aims:
1 CPD credit.
Watch the video and complete the online self-reflection form. Go to "My events" to download your certificate. You must login to watch the video and receive CPD.
This one-day virtual event provided a platform for industry to demonstrate their current products and discuss their pipeline products that will soon be available. This allowed participants to become aware of what the state-of-the-art products in nuclear medicine are and helped them decide what may best suit their needs to improve services.
Educational aims:
- To become aware of state-of-the-art nuclear medicine radiopharmaceuticals and the appropriate indications for use of these products
- To become aware of state-of-the- art imaging cameras to evaluate the advantages and limitations of products
- To learn about current software packages and what functions these can provide
1 CPD credit.
Watch the video and complete the online self-reflection form. Go to "My events" to download your certificate. You must login to watch the video and receive CPD.
Duration:30 mins
Speaker info
Dr Gerhard Dahlhoff
Studied Medicine in Ulm and Munich from 1986 to 1992. Completed the assistant period in Augsburg, Munich, and Lauingen. Passed the speacialist examination in surgery in 2001. Graduated additional Master of Business Administration 2000 in Laar (Germany). Worked as a Senior Physician in Lauingen (Germany) from 1998 to 2000 and at the University of St Gallen (Switzerland) 2000 until 2002. Joined the AOK Bayern (3rd biggest health insurance company of Germany) in 2002-2016 as Chief Medical Direcotr. Took over in 2017 as Chief Medical Director at OncoBeta GmbH and Oncobeta international.